← All trials
NCT05905120
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 2, 2023
- Primary completion
- Jun 30, 2023
- Completion date
- Jul 26, 2023
- First posted
- Jun 15, 2023
- Last posted
- Jul 27, 2023
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Jiao Tong UniversityStudy director
- Yantai UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.